News search

E.g., 18/09/2026
E.g., 18/09/2026
Poster Antibody Responses in Health and Disease: un encuentro internacional para avanzar en el conocimiento de la inmunidad
Dr. Pablo García-Pavía,
About the CNIC
4 Sep 2026

The research demonstrates the benefit of a new gene silencer for treating the disease

Pablo García Pavía y Nerea Mora.
Research
4 Aug 2026

Left ventricular hypertrabeculation, an anatomical feature of the heart traditionally linked to higher risk, does not worsen outcomes in patients with dilated cardiomyopathy

David_Sancho
About the CNIC
20 Jul 2026

The Foundation recognises the pioneering research into the link between gut microbiota and cardiovascular disease led by David Sancho at the CNIC 

Diana Velázquez, Natalia Vicente, Jon Sicilia, María Rosaria Pricolo, Laura Sen, Jorge Alegre y Agata Bak.
Research
7 Jul 2026

Hypertrophic cardiomyopathy is the most common inherited heart disease and the leading cause of sudden cardiac death in young people and athletes

Alzheimer's_Dementia
About the CNIC
6 Jul 2026

This tool paves the way for identifying patients who would be suitable candidates for treatment with anticoagulant therapy already available at the clinic 

Dilated coronary artery in a new experimental model of Kawasaki disease.
Research
1 Jul 2026

The findings provide new insights for developing strategies aimed at preventing the cardiovascular complications associated with this rare disease

Florian Weinberg
About the CNIC
23 Jun 2026

CARDIOSWITCH aims to uncover how the mechanical activity of heart muscle cells shapes cardiac biology and to develop new regenerative strategies for congenital heart disease

About the CNIC
11 Jun 2026

The meeting forms part of European awareness-raising activities around the European Commission’s new strategy to strengthen prevention, early detection, and management of cardiovascular disease

Dr. Pablo García-Pavía junto con la Dra. Noelia Mora y la Dra. Belén Peiró
Research
21 Apr 2026

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.